Mates Sharon 4

What Happened
Sharon Mates, a director of Benitec Biopharma Inc. (BNTC), received a derivative award of 31,500 shares on January 22, 2026. The filing records the transaction price as $0.00, indicating a grant of stock options or similar equity award rather than a purchase. The options will vest on the earlier of the issuer’s next annual stockholders’ meeting or December 1, 2026.

Key Details

• Transaction date: 2026-01-22; Form 4 filed: 2026-01-26 (filed within the SEC’s two-business-day Form 4 deadline).
• Transaction type/code: Award/Grant (Derivative) — 31,500 shares; price reported $0.00.
• Vesting: Options vest on the earlier of the next annual stockholders’ meeting or Dec 1, 2026 (footnote).
• Shares owned after transaction: Not specified in the provided filing details.
• No 10b5-1 plan, tax-withholding, or immediate sale noted in the filing.

Context
This was an equity award to a director (compensation/retention), not an open-market buy or sale. Such grants don’t represent an immediate cash investment by the insider; they become valuable only if and when vested options can be exercised and the stock appreciates. For retail investors, awards are informative about compensation and potential future dilution but aren’t direct bullish/bearish trading signals on their own.